CTOs on the Move

Triumvira

www.triumvira.com

 
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Donna Rill
 Chief Technology Officer Profile

Funding

Triumvira raised $55M on 08/27/2020

Similar Companies

Freeline

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We are headquartered in the UK and we also have operations in Germany and the US. Freeline was founded in 2015 and builds upon the pioneering work by our Clinical and Scientific Advisor and Director, Professor Amit Nathwani, Professor of Haematology at UCL. With our liver-based investigational gene therapy technology, we aim to improve the lives of people with chronic systemic diseases and realise the potential of gene therapy treatments.

R mosaic health

R mosaic health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gel-Del

Gel-Del is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pars Environmental

Pars Environmental is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ikena Oncology

Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.